Physician profile
Kevin E Hunter
NPI 1831248780
$4,086.67
in general payments reported to CMS, 2019-2025
46 companies · $202 in 2025
The $202 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,319 · 2020: $418 · 2021: $579 · 2022: $611 · 2023: $639 · 2024: $317 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,158.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $1,161.33 | 2019-2025 | Mavenclad |
| Alexion Pharmaceuticals, INC. | $433.27 | 2019-2023 | Ultomiris |
| Abbvie INC. | $266.23 | 2019-2025 | |
| Biogen, INC. | $219.37 | 2019-2025 | Leqembi |
| Sk Life Science, INC. | $166.05 | 2022-2023 | |
| Biohaven Pharmaceuticals, INC. | $146.88 | 2021 | |
| Supernus Pharmaceuticals, INC. | $119.48 | 2019 | |
| Jazz Pharmaceuticals INC. | $112.77 | 2019-2022 | |
| Lilly USA, LLC | $103.95 | 2019-2023 | Amyvid |
| Ucb, INC. | $102.72 | 2019-2023 | Briviact |
| Amgen INC. | $96.82 | 2019-2025 | Uplizna |
| Allergan, INC. | $85.06 | 2019-2021 | |
| Genzyme Corporation | $79.78 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $74.63 | 2019-2024 | Austedo Xr |
| Harmony Biosciences LLC | $71.72 | 2020-2023 | Wakix |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.